Breyanzi — Total Revenues
Bristol-Myers Squibb Breyanzi — Total Revenues increased by 4.8% to $411M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 56.3%, from $263M to $411M. Over 4 years (FY 2021 to FY 2025), Breyanzi — Total Revenues shows an upward trend with a 98.8% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates successful market penetration and clinical adoption of the therapy, while a decrease may signal competitive pressure or manufacturing constraints inherent in complex cell therapies.
Detailed definition
This metric represents the total global net sales generated from the commercialization of Breyanzi, a chimeric antigen r...
Peer comparison
Comparable to revenue metrics for specialized oncology or cell-therapy products at major biopharmaceutical peers, often evaluated based on launch trajectory and market share in hematology.
bmy_segment_breyanzi_total_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $17M | $30M | $40M | $44M | $39M | $44M | $55M | $71M | $100M | $92M | $101M | $107M | $153M | $224M | $263M | $263M | $344M | $359M | $392M | $411M |
| QoQ Change | — | +76.5% | +33.3% | +10.0% | -11.4% | +12.8% | +25.0% | +29.1% | +40.8% | -8.0% | +9.8% | +5.9% | +43.0% | +46.4% | +17.4% | +0.0% | +30.8% | +4.4% | +9.2% | +4.8% |
| YoY Change | — | — | — | — | +129.4% | +46.7% | +37.5% | +61.4% | +156.4% | +109.1% | +83.6% | +50.7% | +53.0% | +143.5% | +160.4% | +145.8% | +124.8% | +60.3% | +49.0% | +56.3% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's breyanzi — total revenues?
- Bristol-Myers Squibb (BMY) reported breyanzi — total revenues of $411M in Q1 2026.
- How has Bristol-Myers Squibb's breyanzi — total revenues changed year-over-year?
- Bristol-Myers Squibb's breyanzi — total revenues increased by 56.3% year-over-year, from $263M to $411M.
- What is the long-term trend for Bristol-Myers Squibb's breyanzi — total revenues?
- Over 4 years (2021 to 2025), Bristol-Myers Squibb's breyanzi — total revenues has grown at a 98.8% compound annual growth rate (CAGR), from $87M to $1.36B.
- What does breyanzi — total revenues mean?
- Total revenue generated from the sales of the CAR T-cell therapy product Breyanzi.